Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer
Goldkorn, et al. J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
Aggarwal, et al. Ann Oncol. 2013 Feb;24(2):420-8. doi: 10.1093/annonc/mds336. Epub 2012 Oct 1.
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
Muller, et al. Breast Cancer Res. 2012 Aug 15;14(4):R118. doi: 10.1186/bcr3243.
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
Scher, et al. Lancet Oncol. 2009 Mar;10(3):233-9. doi: 10.1016/S1470-2045(08)70340-1. Epub 2009 Feb 11.
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
de Bono, et al. Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872.
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
Cohen, et al. J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923.
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
Danila, et al. Clin Cancer Res. 2007 Dec 1;13(23):7053-8.
Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer
Budd, et al. Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1769 November 1, 2006 12; 6403-09.
Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer
Cristofanilli, et al. Journal of Clinical Oncology doi: 10.1200/JCO.2005.08.140 JCO March 1, 2005 vol. 23 no. 7 1420-1430
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
Cristofanilli, et al. The new England Journal of Medicine 2004; 351:781-791 August 19, 2004DOI: 10.1056/NEJMoa040766
Circulating tumor cells and [18F]Fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer
De Giorgi, et al. J Clin Oncol 2009 Jul 10;27(20):3303-11. doi: 10.1200/JCO.2008.19.4423. Epub 2009 May 18.
Veridex is now Janssen Diagnostics, which was established in February 2012 within Janssen Pharmaceuticals R&D to bring together personnel with diverse healthcare experiences, skills and knowledge for the purpose of delivering oncology diagnostics to improve clinical outcomes, from discovery to laboratory to patient.
The Safety Data Sheets for In-Vitro Diagnostics are available in multiple languages. Each file below contains a collection of Safety Data Sheets for all reagents within the kit in all three formats - North American, European, and Asia Pacific.
For US Only: As of June 1st, 2015, OSHA requires that Safety Data Sheets include the Globally Harmonized System (GHS) requirements. For the most current version, look for files named "GHS-Compliant English".
Send any questions regarding Safety Data Sheets to SDSJANSSEN@its.jnj.com
CellSave Preservative Tubes (100-Pack) - 7900005 and (20-Pack) - 9528-20
Portuguese – European
Portuguese – Brazilian
CELLSEARCH® Circulating Tumor Cell Control Kit - 7900003
CELLSEARCH® Circulating Tumor Cell Kit - 7900001
CELLTRACKS® AUTOPREP® Instrument Buffer - 7901003